Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany
Albrecht Stenzinger(Heidelberg University), Verena I. Gaidzik(European Bioinformatics Institute), Lars Engstrand(Karolinska Institutet), Silke Laßmann(University of Freiburg), Stefan Fröhling(German Cancer Research Center), Martin Hallbeck(Linköping University), Ambros J. Beer, Melanie Boerries(University of Freiburg), Konstantin Nikolaou(University of Zurich), Richard Rosenquist(Karolinska University Hospital), David Gisselsson(Heidelberg University), Per Sikora(Science for Life Laboratory), Gisela Helenius(Skåne University Hospital), Hans Ehrencrona(Lund University), Michael S. Akhras(Science for Life Laboratory), Peter Kühn(Neu-Ulm University of Applied Sciences), Anders Edsjö(Skåne University Hospital), Peter Horak(German Cancer Research Center), Thoas Fioretos(Lund University), Lucia Cavelier(Uppsala University), Erik Melén(Karolinska Institutet), Lars‐Åke Levin(Johns Hopkins University), Oliver Kohlbacher(Bernstein Center for Computational Neuroscience Tübingen), Robert Thimme(University of Freiburg), Christopher Schroeder, Nisar P. Malek(STZ eyetrial), Carolin Ploeger(Heidelberg University), Mikaela Friedman(Karolinska Institutet), Thomas Seufferlein(Universität Ulm), Lars Palmqvist(Sahlgrenska University Hospital), Lovisa Lovmar(Sahlgrenska University Hospital), Maréne Landström(Uppsala University), Peter Schirmacher(Heidelberg University), Anna Lindstrand(Karolinska University Hospital), Justus Duyster(University of Freiburg), Jan Budczies(German Cancer Research Center), Johan Botling(Uppsala University Hospital), Anna Lena Illert(University of Freiburg), Valtteri Wirta(Karolinska University Hospital), Michael Bitzer(University Children's Hospital Tübingen), Anna Wedell(Karolinska University Hospital), Mia Wadelius(Uppsala University)
Cited by 38
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
|Nature|2011|1.6k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k